Nonsurgical ACL Treatment Studied With Success

A clinical study of 47 patients found that a cell-based injection therapy allowed most to return to their prior athletic activity.

Updated on Oct. 14, 2026 in Arthritis

Isometric editorial illustration showing a medical syringe and a stylized knee joint model on a clean surface, representing non-invasive orthopedic treatment.
A July 2026 clinical study demonstrated that a cell-based injection therapy allowed nearly all patients to recover from ACL ruptures without surgery. AI Illustration. Upload story photo >

Live Poll

Would you prefer a nonsurgical approach for ACL injury treatment if it were available?

In July 2026, researchers published results from a clinical study involving 47 patients who underwent a nonsurgical treatment for ACL ruptures. Using the Miracell system, the procedure utilized concentrated cells and platelet-rich plasma to promote healing.

Why it matters

This study highlights a potential shift in orthopedic recovery, as 46 of the 47 participants successfully returned to their pre-injury sports activity levels without traditional reconstruction. The findings suggest that non-invasive cell-based therapies could offer a viable alternative to surgery for ligament repair.

Participants achieved an average knee function score of 94 out of 100 on standardized assessments after one year. Average pain scores dropped from 3.36 at four weeks post-treatment to 0.36 after 12 months.

The players

Miracell

This is a South Korea-based medical technology company that develops cell-processing systems for clinical applications.

The details

Patients in the study received injections of concentrated cells derived from their own blood, processed by the Smart M-Cell system, and combined with platelet-rich plasma. All participants completed a standardized rehabilitation program following the procedure.

Timeline

  1. April 2026: Miracell received FDA 510(k) clearance for cell-processing systems.

  2. July 2026: The clinical study results were published.

  3. 4 weeks after treatment: Average pain scores measured 3.36.

  4. 12 months after treatment: Average pain scores measured 0.36.

Health Landscape

The FDA 510(k) clearance for the Smart M-Cell system marks a regulatory milestone that enables its use in standardized clinical procedures. This study reflects a broader push in regenerative medicine to integrate cell-based treatments into standard orthopedic care protocols.

Patients facing ACL ruptures may eventually have access to less invasive recovery options that bypass the risks of reconstruction surgery. These procedures require a consistent commitment to a standardized rehabilitation program to achieve full activity recovery.

The takeaway

The study demonstrates that non-surgical, cell-based interventions may provide an effective recovery path for ligament injuries. Patients should consult with orthopedic specialists to discuss whether such emerging technologies are appropriate for their specific injury profile.

Further reading

Find more clinical developments in the Arthritis section.

Source note: This article includes information reported by The Korea Herald.

Live Poll

Would you prefer a nonsurgical approach for ACL injury treatment if it were available?